Financhill
Sell
32

RYTM Quote, Financials, Valuation and Earnings

Last price:
$56.16
Seasonality move :
-21.98%
Day range:
$55.69 - $56.99
52-week range:
$35.17 - $68.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
30.15x
P/B ratio:
307.81x
Volume:
590.7K
Avg. volume:
539.2K
1-year change:
32.13%
Market cap:
$3.5B
Revenue:
$77.4M
EPS (TTM):
-$4.33

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RYTM
Rhythm Pharmaceuticals
$37.5M -$0.75 48.25% -15.36% $73.18
KRYS
Krystal Biotech
$91.4M $1.85 116.67% 497.44% $206.25
MNKD
MannKind
$75.3M $0.03 28.05% 200% $9.80
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 -60.77% -99.16% $7.30
TGTX
TG Therapeutics
$98.3M $0.08 124.69% -95.36% $40.88
VYGR
Voyager Therapeutics
$16.6M -$0.35 -82.84% -31.36% $17.10
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RYTM
Rhythm Pharmaceuticals
$56.17 $73.18 $3.5B -- $0.00 0% 30.15x
KRYS
Krystal Biotech
$152.92 $206.25 $4.4B 85.91x $0.00 0% 18.63x
MNKD
MannKind
$6.09 $9.80 $1.7B 76.13x $0.00 0% 6.57x
NBY
NovaBay Pharmaceuticals
$0.70 $7.30 $3.4M -- $0.00 0% 0.07x
TGTX
TG Therapeutics
$28.88 $40.88 $4.5B 39.15x $0.00 0% 16.97x
VYGR
Voyager Therapeutics
$5.45 $17.10 $297.7M 8.38x $0.00 0% 1.86x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RYTM
Rhythm Pharmaceuticals
-- 2.045 -- 3.25x
KRYS
Krystal Biotech
-- 4.158 -- 7.66x
MNKD
MannKind
1265.29% 1.713 13.14% 3.74x
NBY
NovaBay Pharmaceuticals
4.54% 0.365 1.51% 0.75x
TGTX
TG Therapeutics
55.96% 3.207 6.7% 3.65x
VYGR
Voyager Therapeutics
-- 1.704 -- 8.26x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RYTM
Rhythm Pharmaceuticals
$29.4M -$43.9M -208.96% -208.96% -116.52% $14.8M
KRYS
Krystal Biotech
$77.2M $34.9M 6.45% 6.45% 41.67% $57.8M
MNKD
MannKind
$52.1M $15.2M 110.06% -- 30.29% $7.9M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
TGTX
TG Therapeutics
$74.5M $12.4M -4.78% -8.4% 18% -$12.2M
VYGR
Voyager Therapeutics
-- -$13.8M 9.12% 9.12% -55.95% -$28.2M

Rhythm Pharmaceuticals vs. Competitors

  • Which has Higher Returns RYTM or KRYS?

    Krystal Biotech has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of 32.42%. Rhythm Pharmaceuticals's return on equity of -208.96% beat Krystal Biotech's return on equity of 6.45%.

    Company Gross Margin Earnings Per Share Invested Capital
    RYTM
    Rhythm Pharmaceuticals
    88.49% -$0.73 $11.2M
    KRYS
    Krystal Biotech
    92.03% $0.91 $885.8M
  • What do Analysts Say About RYTM or KRYS?

    Rhythm Pharmaceuticals has a consensus price target of $73.18, signalling upside risk potential of 30.29%. On the other hand Krystal Biotech has an analysts' consensus of $206.25 which suggests that it could grow by 34.87%. Given that Krystal Biotech has higher upside potential than Rhythm Pharmaceuticals, analysts believe Krystal Biotech is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RYTM
    Rhythm Pharmaceuticals
    6 1 0
    KRYS
    Krystal Biotech
    7 1 0
  • Is RYTM or KRYS More Risky?

    Rhythm Pharmaceuticals has a beta of 2.165, which suggesting that the stock is 116.542% more volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.852, suggesting its less volatile than the S&P 500 by 14.794%.

  • Which is a Better Dividend Stock RYTM or KRYS?

    Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RYTM or KRYS?

    Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are smaller than Krystal Biotech quarterly revenues of $83.8M. Rhythm Pharmaceuticals's net income of -$43.6M is lower than Krystal Biotech's net income of $27.2M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 85.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 30.15x versus 18.63x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RYTM
    Rhythm Pharmaceuticals
    30.15x -- $33.3M -$43.6M
    KRYS
    Krystal Biotech
    18.63x 85.91x $83.8M $27.2M
  • Which has Higher Returns RYTM or MNKD?

    MannKind has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of 16.48%. Rhythm Pharmaceuticals's return on equity of -208.96% beat MannKind's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RYTM
    Rhythm Pharmaceuticals
    88.49% -$0.73 $11.2M
    MNKD
    MannKind
    74.28% $0.04 $18M
  • What do Analysts Say About RYTM or MNKD?

    Rhythm Pharmaceuticals has a consensus price target of $73.18, signalling upside risk potential of 30.29%. On the other hand MannKind has an analysts' consensus of $9.80 which suggests that it could grow by 60.92%. Given that MannKind has higher upside potential than Rhythm Pharmaceuticals, analysts believe MannKind is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RYTM
    Rhythm Pharmaceuticals
    6 1 0
    MNKD
    MannKind
    4 0 0
  • Is RYTM or MNKD More Risky?

    Rhythm Pharmaceuticals has a beta of 2.165, which suggesting that the stock is 116.542% more volatile than S&P 500. In comparison MannKind has a beta of 1.289, suggesting its more volatile than the S&P 500 by 28.87%.

  • Which is a Better Dividend Stock RYTM or MNKD?

    Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. MannKind pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RYTM or MNKD?

    Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are smaller than MannKind quarterly revenues of $70.1M. Rhythm Pharmaceuticals's net income of -$43.6M is lower than MannKind's net income of $11.6M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while MannKind's PE ratio is 76.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 30.15x versus 6.57x for MannKind. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RYTM
    Rhythm Pharmaceuticals
    30.15x -- $33.3M -$43.6M
    MNKD
    MannKind
    6.57x 76.13x $70.1M $11.6M
  • Which has Higher Returns RYTM or NBY?

    NovaBay Pharmaceuticals has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of -49.65%. Rhythm Pharmaceuticals's return on equity of -208.96% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    RYTM
    Rhythm Pharmaceuticals
    88.49% -$0.73 $11.2M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About RYTM or NBY?

    Rhythm Pharmaceuticals has a consensus price target of $73.18, signalling upside risk potential of 30.29%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 434.43%. Given that NovaBay Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RYTM
    Rhythm Pharmaceuticals
    6 1 0
    NBY
    NovaBay Pharmaceuticals
    2 0 0
  • Is RYTM or NBY More Risky?

    Rhythm Pharmaceuticals has a beta of 2.165, which suggesting that the stock is 116.542% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

  • Which is a Better Dividend Stock RYTM or NBY?

    Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RYTM or NBY?

    Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Rhythm Pharmaceuticals's net income of -$43.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 30.15x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RYTM
    Rhythm Pharmaceuticals
    30.15x -- $33.3M -$43.6M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns RYTM or TGTX?

    TG Therapeutics has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of 4.63%. Rhythm Pharmaceuticals's return on equity of -208.96% beat TG Therapeutics's return on equity of -8.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    RYTM
    Rhythm Pharmaceuticals
    88.49% -$0.73 $11.2M
    TGTX
    TG Therapeutics
    88.86% $0.02 $436.3M
  • What do Analysts Say About RYTM or TGTX?

    Rhythm Pharmaceuticals has a consensus price target of $73.18, signalling upside risk potential of 30.29%. On the other hand TG Therapeutics has an analysts' consensus of $40.88 which suggests that it could grow by 41.53%. Given that TG Therapeutics has higher upside potential than Rhythm Pharmaceuticals, analysts believe TG Therapeutics is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RYTM
    Rhythm Pharmaceuticals
    6 1 0
    TGTX
    TG Therapeutics
    6 0 0
  • Is RYTM or TGTX More Risky?

    Rhythm Pharmaceuticals has a beta of 2.165, which suggesting that the stock is 116.542% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.245, suggesting its more volatile than the S&P 500 by 124.477%.

  • Which is a Better Dividend Stock RYTM or TGTX?

    Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RYTM or TGTX?

    Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are smaller than TG Therapeutics quarterly revenues of $83.9M. Rhythm Pharmaceuticals's net income of -$43.6M is lower than TG Therapeutics's net income of $3.9M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 39.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 30.15x versus 16.97x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RYTM
    Rhythm Pharmaceuticals
    30.15x -- $33.3M -$43.6M
    TGTX
    TG Therapeutics
    16.97x 39.15x $83.9M $3.9M
  • Which has Higher Returns RYTM or VYGR?

    Voyager Therapeutics has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of -36.72%. Rhythm Pharmaceuticals's return on equity of -208.96% beat Voyager Therapeutics's return on equity of 9.12%.

    Company Gross Margin Earnings Per Share Invested Capital
    RYTM
    Rhythm Pharmaceuticals
    88.49% -$0.73 $11.2M
    VYGR
    Voyager Therapeutics
    -- -$0.16 $330.3M
  • What do Analysts Say About RYTM or VYGR?

    Rhythm Pharmaceuticals has a consensus price target of $73.18, signalling upside risk potential of 30.29%. On the other hand Voyager Therapeutics has an analysts' consensus of $17.10 which suggests that it could grow by 213.76%. Given that Voyager Therapeutics has higher upside potential than Rhythm Pharmaceuticals, analysts believe Voyager Therapeutics is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RYTM
    Rhythm Pharmaceuticals
    6 1 0
    VYGR
    Voyager Therapeutics
    10 0 0
  • Is RYTM or VYGR More Risky?

    Rhythm Pharmaceuticals has a beta of 2.165, which suggesting that the stock is 116.542% more volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.053%.

  • Which is a Better Dividend Stock RYTM or VYGR?

    Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RYTM or VYGR?

    Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are larger than Voyager Therapeutics quarterly revenues of $24.6M. Rhythm Pharmaceuticals's net income of -$43.6M is lower than Voyager Therapeutics's net income of -$9M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 8.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 30.15x versus 1.86x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RYTM
    Rhythm Pharmaceuticals
    30.15x -- $33.3M -$43.6M
    VYGR
    Voyager Therapeutics
    1.86x 8.38x $24.6M -$9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

4 Top Dividend Stocks to Buy Now
4 Top Dividend Stocks to Buy Now

If you’re looking for steady income, dividend stocks are a…

Will Uber Stock Recover?
Will Uber Stock Recover?

Shares of Uber Technologies (NYSE:UBER) have had a rough few…

Is ARK Next Generation Internet ETF a Good Investment?
Is ARK Next Generation Internet ETF a Good Investment?

The ARK Next Generation Internet ETF looks like a pretty…

Stock Ideas

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Sell
47
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 114x

Sell
39
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 36x

Alerts

Buy
87
CEG alert for Jan 11

Constellation Energy [CEG] is up 25.15% over the past day.

Sell
1
MCY alert for Jan 11

Mercury General [MCY] is down 19.87% over the past day.

Buy
84
ATZAF alert for Jan 11

Aritzia [ATZAF] is up 17.63% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock